Efficacy and safety of primary and repeated therapy courses of Parkinson’s disease with autologous mesenchymal stromal cells in the long-term period

Parkinson’s disease (PD) is a chronic progressive disease. Currently, PD treatment is symptomatic. One of the promising directions changing the PD therapy course is the use of autologous multipotent mesenchymal stromal cells (MMSCs). Despite the encouraging results in various preclinical and clinical trials and proven safety, the cell therapy questions remain open, such as the choice of an optimal route of administration, dose, and frequency of treatment courses.In the present study, the dynamics of PD motor and non-motor symptoms was assessed after the first and second cell therapy courses using MMSC injections via systemic and tandem methods during a long-term period. A positive therapy effect on the dynamics of motor and non-motor symptoms in patients with PD was revealed for an average of 6 months after one MMSC treatment course. The repeated MMSC treatment course has similar efficacy and safety to the first course and can be used to slow down the PD progression for a longer period.